암면역치료 연관 내분비 이상반응

키워드

참고문헌 (38)

1. Ott PA, "CTLA-4 and PD-1", PD-L1blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients, 2013, pp.19(19), 5300~5309
2. Joshi MN, "Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review", Clin Endocrinol (Oxf), 85(3), pp.331~339 (2016)
3. Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366(26), pp.2443~2454 (2012)
4. Guaraldi F, "Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution", J Endocrinol Invest, 41(5), pp.549~556 (2018)
5. Chalan P, "Thyroid dysfunctions secondary to cancer immunotherapy", J Endocrinol Invest, 41(6), pp.625~638 (2018)
6. Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma", N Engl J Med, 372(26), pp.2521~2532 (2015)
7. Faje AT, "Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma", J Clin Endocrinol Metab, 99(11), pp.4078~4085 (2014)
8. Dillard T, "Anti-CTLA-4antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes", Pituitary, 13(1), pp.29~38 (2010)
9. Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363(8), pp.711~723 (2010)
10. Ryder M, "Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution", Endocr Relat Cancer, 21(2), pp.371~381 (2014)
11. Larkin J, "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma", N Engl J Med, 373(1), pp.23~34 (2015)
12. Morganstein DL, "Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma", Clin Endocrinol (Oxf), 86(4), pp.614~620 (2017)
13. de Filette J, "Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab", J Clin Endocrinol Metab, 101(11), pp.4431~4439 (2016)
14. Orlov S, "Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies", J Clin Endocrinol Metab, 100(5), pp.1738~1741 (2015)
15. Iyer PC, "Immune-related thyroiditis with immune checkpoint inhibitors", Thyroid, 28(10), pp.1243~1251 (2018)
16. Michot JM, "Immune-related adverse events with immune checkpoint blockade: a comprehensive review", Eur J Cancer, 54, pp.139~148 (2016)
17. Horvat TZ, "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center", J Clin Oncol, 33(28), pp.3193~3198 (2015)
18. Weber JS, "Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma", Cancer, 119(9), pp.1675~1682 (2013)
19. Bellastella G, "Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects", Pituitary, 19(6), pp.625~642 (2016)
20. Corsello SM, "Endocrine side effects induced by immune checkpoint inhibitors", J Clin Endocrinol Metab, 98(4), pp.1361~1375 (2013)
21. Marlier J, "Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports", Endocrine, 47(3), pp.878~883 (2014)
22. Iglesias P, "Cancer immunotherapy-induced endocrinopathies:clinical behavior and therapeutic approach", Eur J Intern Med, 47, pp.6~13 (2018)
23. Laurent S, "The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production", J Transl Med, 11, pp.108~ (2013)
24. Iwama S, "Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody", Sci Transl Med, 6(230), pp.230~245 (2014)
25. Min L, "Ipilimumab-induced autoimmune adrenalitis", Lancet Diabetes Endocrinol, 1(3), pp.e15~ (2013)
26. Howard SA, "A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy", AJR Am J Roentgenol, 207(1), pp.4~14 (2016)
27. Mellati M, "Anti-PD-1 and Anti-PDL-1monoclonal antibodies causing type 1 diabetes", Diabetes Care, 38(9), pp.e137~e138 (2015)
28. Hughes J, "Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy", Diabetes Care, 38(4), pp.e55~e57 (2015)
29. Martin-Liberal J, "Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report", Cancer Immunol Immunother, 64(6), pp.765~767 (2015)
30. Gaudy C, "Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes", Diabetes Care, 38(11), pp.e182~e183 (2015)
31. Lowe JR, "Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy", J Immunother Cancer, 4, pp.89~ (2016)
32. Chae YK, "A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1diabetes", Cancer Immunol Immunother, 66(1), pp.25~32 (2017)
33. Win MA, "Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism", Am J Emerg Med, 35(7), pp.1039~ (2017)
34. Indini A, "Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma", J Cancer Res Clin Oncol, 145(2), pp.511~521 (2019)
35. Ricciuti B, "Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multiinstitutional analysis", J Cancer Res Clin Oncol, 145(2), pp.479~485 (2019)
36. Abu-Sbeih H, "The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes", J Immunother Precis Oncol, 1(1), pp.7~18 (2018)
37. Soularue E, "Enterocolitis due to immune checkpoint inhibitors: a systematic review", Gut, 67(11), pp.2056~2067 (2018)
38. Ruggeri RM, "Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)", J Endocrinol Invest, 42(7), pp.745~756 (2019)

관련 논문AI추천